Best Genomics Companies in Japan
The 75 best Genomics companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Modalis Therapeutics.
- Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 202
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Japan
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Modalis Therapeutics Developer of CRISPR based therapeutics for monogenic disorders | $61M | 85 mo ago | Public | 29 29 → 22 (-24%) | Haru Morita Co-Founder | Top 5M | 108 patents CRISPR‑based gene therapies targeting disease‑causing genes for muscular dystrophy and Alzheimer’s | — |
| 2 | Genesis Healthcare Provider of consumer kits and genomic services for researchers | $35M | 99 mo ago | Series A | 20 | David Balan Co-Founder | Top 50M | — | — |
| 3 | Cykinso Direct-to-consumer tests for intestinal microbiome profiling | $16M | 2 mo ago | Series D | 15 | — | Top 10M | 6 patents AI-driven pet nutrition recommendation and gastrointestinal health diagnostic technologies | — |
| 4 | Molcure Provider of AI-based platform for drug discovery and design | $12M | 58 mo ago | Series C | 33 | Yutaro Kyono Co-Founder & CTO | — | 10 patents Protein‑binding assay technologies and bubble‑generation systems for drug delivery | — |
| 5 | Craif Developer of a device for cancer detection | $11M | 13 mo ago | Series C | 12 | Takao Yasui Co-Founder | Top 5M | 48 patents Microfluidic bioseparation and molecular diagnostics for biomarkers and genetic disease testing | — |
| 6 | OriCiro Genomics Developer of technologies for DNA synthesis and amplification | $11M | 48 mo ago | Acquired | 10 | — | — | 47 patents Cell‑free DNA synthesis, circular DNA production, and enzymatic DNA editing/assembly technologies. | — |
| 7 | Edit Force Developer of gene editing tools | $10M | 37 mo ago | Series B | — | Takashi Ono CEO | Top 10M | — | — |
| 8 | Momotaro-Gene Provider of gene therapy to treat cancer | $10M | 38 mo ago | Series A | 7 | — | — | 92 patents Gene therapy delivering REIC/Dkk-3 for cancer immunotherapy and EGFR‑mutant lung cancer | — |
| 9 | Gra And Green Developer of genome editing technologies and advanced breeding for crops | $8M | 23 mo ago | Series C | 37 | — | Top 5M | 20 patents Plant genome editing and promoter engineering using site-specific nucleases. | — |
| 10 | Repertoire TCR/BCR repertoire analysis services | $6M | 118 mo ago | Acquired | 20 | Ryuji Suzuki CEO & President | — | — | — |
| 11 | Rhelixa Provider of integrated genomic analysis platform | $6M | 22 mo ago | Series B | 56 | — | Top 5M | 2 patents Personalized biological age assessment using nucleic‑acid biomarkers and related data generation tools | — |
| 12 | Miltel Provider of telomere test for detection of aging | $5M | 30 mo ago | Series A | 27 | Eitoshi Tahara Founder | Top 5M | — | — |
| 13 | AccuRna Provider of nucleic acid therapeutics using drug delivery platform | $5M | 101 mo ago | Seed | 23 | Shiro Akinaga CEO | — | 10 patents Patents concentrated in health & consumer products | — |
| 14 | TAGCyx Provider of nucleic acid-based drug discovery platform | $5M | 59 mo ago | Series B | 18 | — | Top 10M | — | — |
| 15 | Ribomic Developer of aptamer-based therapeutics for the treatment of multiple diseases | $4M | 224 mo ago | Public | 25 | — | Top 5M | 227 patents Aptamer-based therapeutics targeting FGF2 for ocular disease treatment | — |
| 16 | Synplogen Developer of technology for DNA synthesis | $4M | 16 mo ago | Series D | — | Junichi Sugahara CEO | — | 62 patents Engineered nucleic acid vectors and plasmids for enhanced protein expression and production | — |
| 17 | Molecular and Clinical Bioinformatics Provider of biomarkers to detect mild cognitive impairment | $3M | 40 mo ago | Series A | 30 | Kazuhiko Uchida CEO & President | Top 10M | — | — |
| 18 | Platinum Bio Developer of gene editing technology | $3M | 32 mo ago | Series A | 12 | Takashi Yamamoto Co-Founder | Top 50M | — | 1 launch · 1 expansion · 1 award |
| 19 | Chromocenter Tools for cell line development | $2M | 118 mo ago | Seed | 10 | — | — | 5 patents Chromosome engineering tools for artificial chromosomes, gene amplification, and cytogenetic diagnostics | — |
| 20 | Fermelanta Provider of a biotech company that uses microbial fermentation to produce plant-based chemicals, including… | $1M | 9 mo ago | Series A | — | Hiromichi Minami Co-Founder & CSO | Top 50M | — | 2 awards |
Top 12 Genomics companies in Japan
#1
Series D · Shibuya, Tokyo · founded 2014 · 15 employees$15.7Mraised▾
Direct-to-consumer tests for intestinal microbiome profiling. Its flagship product Mykinso uses next-generation sequencing and proprietary bioinformatics for metagenomic profiling of the customer's stool sample. Users can purchase the fecal sample kit, register it online and mail the sample to the company. In addition, they are encouraged to fill in a lifestyle-related questionnaire that Cykinso plans to use in future research. Results can be viewed on the company website or the accompanying app.
- Apr 2026Series D—
- Aug 2024Series D$7.6M
- Jul 2023Series D$5.7M
- Dec 2016Series A$2.3M
#2
Series C · Tokyo, Tokyo · founded 2018 · 12 employees$11.3Mraised▾
Developer of a device for cancer detection. The company has developed a novel device that is used to collect and separate the microRNA secreted from cancer cells present in the urine. The device uses a combination of zinc oxide nanostructures and microflow channel technologies for the process and early cancer detection.
- Apr 2025Series C$22M
- Dec 2024Series C$6.4M
- Mar 2024Series B—
- Apr 2022Series B—
#3
Series A · Nonoichi, Ishikawa · founded 2022$1.4Mraised▾
Provider of a biotech company that uses microbial fermentation to produce plant-based chemicals, including secondary metabolites for use in medicines, cosmetics, and health foods.
- Sep 2025Grant (prize money)—
- Aug 2025Series A$13.6M
- Jun 2023Seed$1.4M
#4
Series D · Tsuruoka, Yamagata · founded 2017$3.8Mraised▾
Developer of technology for DNA synthesis. It offers its flagship technology OGAB which is a used to synthesize 50 DNA at once utilizing Bacillus subtilis and Combi-OGCB for the synthesis of the cluster of genes from microbes. It offers its services of long-chain DNA synthesis, DNA library synthesis, and microbial-based production for genetic engineering approaches to different medical, biotechnological and food industries.
- Jan 2025Series D$3.8M
- Feb 2023Series C—
- Nov 2021Seed—
- May 2019Seed—
#5
Series C · Nagoya, Aichi · founded 2017 · 37 employees$8.1Mraised▾
Developer of genome editing technologies and advanced breeding for crops. It focuses on developing seeds and seedlings that require fewer resources. The company aims to minimize the inputs needed for crop cultivation. This includes improving fertilizer utilization and enhancing resistance to diseases and environmental stresses. The goal is to increase crop yields and improve the preservation and processing qualities of crops. The company also offers collaborative research and development services.
- Jun 2024Series C$4.1M
- Apr 2022Series B$4M
#6
Series B · Chiyoda City, Tokyo · founded 2015 · 56 employees$5.6Mraised▾
Provider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services.
- Aug 2024Series B$3.4M
- Nov 2018Seed$2.2M
#7
Public · Tokyo, Tokyo · founded 2016 · 29 employees$60.7Mraised▾
MODALIS is a developer of therapeutics based on CRISPR technology. The company is developing CRISPR-based therapeutics for treating monogenic disorders caused due to malfunctioned genes.
- May 2019Series B$8M
- Apr 2019Series B$14.4M
- Feb 2019Series A$10M
- Aug 2018Series A$15M
#8
Series B · Fukuoka, Fukuoka · founded 2015$10.5Mraised▾
Developer of gene editing tools for reagents, pharmaceuticals, agriculture, chemical production. The company has developed pentatricopeptide repeat (PPR) proteins that target the base sequences of DNA and RNA.
- May 2023Series B$2.2M
- May 2021Series B—
- Mar 2019Series B$7.8M
- Nov 2017Series A$2.6M
#9
Series A · Okayama, Okayama · founded 2007 · 7 employees$9.7Mraised▾
Provider of gene therapy to treat cancer. The company believes REIC can selectively kill cancer cells without harming normal cells, induce potent anti-tumor immunity, which leads to preventing cancer, and also develop new molecular targeting drugs. They currently focus on realizing Phase I/II clinical study for prostate cancer and malignant mesothelioma in the US and Japan to establish its proof of concept (POC). After the POC establishment, the company would like to research and expand to other cancer types with various gene carriers, and its new molecular target drug-using REIC protein or peptide.
- Apr 2023Series A$3.8M
- Mar 2019Series A$4.9M
- Mar 2017Series A$9.7M
#10
Series A · Hiroshima, Hiroshima · founded 2012 · 27 employees$5.3Mraised▾
Provider of telomere test for detection of aging. The company provides this test to estimate gene strength produced and gene fatigue due to daily stress. The test, thus, helps in determining the cellular senescence.
- Nov 2023Series A—
- Jun 2018Series A$5.3M
- Nov 2015Seed—
#11
Acquired · Tokyo, Tokyo · founded 2018 · 10 employees$10.9Mraised▾
Developer of technologies for DNA synthesis and amplification. The company has an OriCiro Cell-Free Cloning System which is composed of OriCiro Assembly Kit and OriCiro Amp Kit that enables cell-free assembly and amplification of circular DNA molecules.
- Jun 2022Series B—
- Jul 2021Series B$7.3M
- Jul 2021Conventional Debt$1.8M
- Apr 2019Series A$3.6M
#12
Series A · Tokyo, Tokyo · founded 2004 · 20 employees$35.4Mraised▾
Provider of consumer kits and genomic services for researchers. The company's GeneLife helps the consumers to order a sample kit and process for obesity and skincare management. It also provides Genesis Pro which helps in using PCR, microarray, and next-generation sequencing services, along with bioinformatics interpretation services. Its testing menu includes DNA extraction, SNPs genotyping, pharmacogenetics, periodontal genetic testing, gene expression, forensic testing, and population genetics.
- Feb 2018Series A$15.5M
- Aug 2017Series A$13.8M
- 2014Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Japan
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,330 Japan-affiliated papers.
- The University of Tokyo147
- Kyoto University82
- Korea University65
- The University of Osaka59
- Keio University43
- Gene5→74
- Genome9→76
- Identification (biology)2→31
- Immune system1→25
- Disease1→24
- Gene1→32
- Transcriptome1→24
- Cancer3→20
- Identification (biology)1→9
- microRNA1→8
- Genome1→11
- Mechanism (biology)1→7
- Gene1→4
Where bioinformatics is researched across Japan
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.